Drug costs in context: assessing drug costs in cost-of-illness analyses

T Joseph Mattingly II, Shannon Weathers

Article Type

Commentary

Published

This article aims to provide contextual information for a general audience interested in conducting or evaluating cost-of-illness studies that may include drug costs and to describe key factors to consider when reviewing drug costs in the peer-reviewed literature.

Read more

Overcoming hurdles: measurement of health-related outcomes associated with national level medicines usage in Ireland

Gary L O’Brien BPharm, MPharm, Muireann McAlister BSc Pharmacy, Stephen Byrne BSc Pharmacy, PhD, James Gallagher BPharm, MPharm, PhD

Article Type

Editorial

Published

This editorial provides an overview of the evolving healthcare landscape surrounding medicine usage estimation and valuation in Ireland and offers recommendations on how improved methods of measuring health-related outcomes may help ameliorate efficiencies and the sustainability of a healthcare system.

Read more

Considerations for the US health-system pharmacist in a world of biosimilars

Andrea Zlatkus CRHC, Todd Bixby RPh, Kavitha Goyal MD

Article Type

Editorial

Published

This editorial article provides an overview of the evolving healthcare landscape shaped by the entry of multiple biosimilars, including for a given reference product, and their impact on the healthsystem pharmacist with respect to formulary assessment, implementation, and education of various health-system stakeholders, including patients.

Read more

Register for alerts

I would like to be contacted by Drugs in Context when new articles are posted.